Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in progressive advanced/metastatic well-differentiated pancreatic neuroendocrine tumors
NCT01121562Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in Pancreatic neuroendocrine tumor (PanNET), sponsored by Pfizer. Primary endpoint: Clinical Benefit Response Rate up to 799 days. Started Jul 2010; status: completed.
02
Drugs
sunitinib
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT01121562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01121562.